Skip to content
Screener

Spyre Therapeutics, Inc. SYRE Q4 2025 Annual earnings

Reported February 19, 2026 · Before market open

Revenue$90.5MMiss by $52.4M
EPS-$0.70Miss by $0.04
Revenue estimate$142.9M
EPS estimate-$0.66

Next report

Nov 3, 2026 (in 2 months)
EPS estimate-$0.80

Financials

Q4 2025

Income statement

See full
Revenue-—
Operating income-$57.2M+6.7%
Net income-$62.5M-11.1%
EPS (diluted)-$0.74-208%

Balance sheet

See full
Cash & equivalents$85.7M-4.1%
Total equity$715.2M+38.1%
Total assets$777.8M+27.8%

Cash flow

See full
Operating cash flow-$44.6M-19.8%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$2.54B+82.6%

Returns & leverage

See full
Return on equity-25.2%-9.2pp
Current ratio13.3×+2.0×

Segments

By segment

See full
Reportable Segment-—

Versus estimates

Revenue

Q4 2025$90.5MMiss by $52.4M

Diluted EPS

Q2 2026-$0.36Beat by $0.40Q1 2026-$0.74Miss by $0.08
Q4 2025-$0.70Miss by $0.04
Q3 2025-$0.15Beat by $0.53Q2 2025-$0.49Beat by $0.24Q1 2025-$0.74Beat by $0.02

FAQ

When did Spyre Therapeutics, Inc. report Q4 2025 earnings?
Spyre Therapeutics, Inc. (SYRE) reported Q4 2025 earnings on February 19, 2026 before market open.
What were Spyre Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Spyre Therapeutics, Inc. reported revenue of $90.5M and eps of $-0.70 for Q4 2025.
Did Spyre Therapeutics, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $142.9M by $52.4M. EPS missed the consensus estimate of $-0.66 by $0.04.
How did Spyre Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 13.6% from $-0.81.
Where can I find Spyre Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001636282-26-000022) and the 10-K periodic report (0001636282-26-000020) directly on SEC EDGAR. The filing index links above go to sec.gov.